International Co. For Investment & Development (EGX:ICID)

Sage Therapeutics Cash Flow Statement

Financials in millions EGP. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	13.9	10.38	4.36	3.06	7.69	2.2
Depreciation & Amortization	0.02	0.02	0.02	0.02	0.02	0.02
Loss (Gain) From Sale of Assets	-0.64	-0.64	-0.76	-	-6.92	-
Loss (Gain) From Sale of Investments	-	-	-	0.01	-	0.01
Loss (Gain) on Equity Investments	-5.33	-2.73	-2.73	-1.66	-1.43	-0.88
Provision & Write-off of Bad Debts	0.98	0.98	-	-	-	-
Other Operating Activities	3.39	2.03	-0.22	-0.07	0.63	-0.2
Change in Accounts Receivable	-0.54	-0.51	-	3.12	12.3	-7.26
Change in Accounts Payable	0.62	0.58	-	-0.48	-12.08	7.46
Change in Other Net Operating Assets	-20.41	-14.89	12.44	-3.44	-2.76	-1.21
Operating Cash Flow	-8.03	-4.78	13.12	0.57	-2.54	0.14
Operating Cash Flow Growth	-	-	2205.07%	-	-	-90.60%
Capital Expenditures	-	-	-0	-0.44	-0.03	-0.04
Sale of Property, Plant & Equipment	0.68	0.68	0.8	-	3.65	-
Cash Acquisitions	-	-	-7.5	-	-	-
Investment in Securities	6.89	-0.37	-6.23	-	-	0.03
Investing Cash Flow	6.6	0.31	-12.93	-0.44	3.62	-0
Issuance of Common Stock	-	46	-	-	-	-
Common Dividends Paid	-	-	-	-	-1.07	-
Other Financing Activities	10	10	-	-0.01	-	-
Financing Cash Flow	10	56	-	-0.01	-1.07	-
Net Cash Flow	8.57	51.53	0.19	0.11	0.01	0.13
Free Cash Flow	-8.03	-4.78	13.12	0.13	-2.57	0.1
Free Cash Flow Growth	-	-	10143.64%	-	-	-93.13%
Free Cash Flow Margin	-73.45%	-54.52%	102.48%	1.75%	-46.62%	0.55%
Free Cash Flow Per Share	-0.09	-0.05	0.13	0.00	-0.05	0.00
Cash Income Tax Paid	0.49	0.49	0.7	0.72	0.64	0.7
Levered Free Cash Flow	-16.65	-12.85	10.67	12.36	-5	0.07
Unlevered Free Cash Flow	-16.65	-12.85	10.67	12.36	-5	0.07
Change in Net Working Capital	17.16	11.94	-9.8	-11.49	5.37	1.07

Source: S&P Global Market Intelligence. Standard template. Financial Sources.